Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
Department of Microbiology, Quaid-i-Azam University, Islamabad, Pakistan.
Infect Genet Evol. 2021 Aug;92:104861. doi: 10.1016/j.meegid.2021.104861. Epub 2021 Apr 20.
Whole genome sequencing (WGS) is one of the most reliable methods for detection of drug resistance, genetic diversity in other virulence factor and also evolutionary dynamics of Mycobacterium tuberculosis complex (MTBC). First-line anti-tuberculosis drugs are the major weapons against Mycobacterium tuberculosis (MTB). However, the emergence of drug resistance remained a major obstacle towards global tuberculosis (TB) control program 2030, especially in high burden countries including Pakistan. To overcome the resistance and design potent drugs, genomic variations in drugs targets as well as in the virulence and evolutionary factors might be useful for better understanding and designing potential inhibitors. Here we aimed to find genomic variations in the first-line drugs targets, along with other virulence and evolutionary factors among the circulating isolates in Khyber Pakhtunkhwa, Pakistan. Samples were collected and drug susceptibility testing (DST) was performed as per WHO standard. The resistance samples were subjected to WGS. Among the five whole genome sequences, three samples (NCBI BioProject Accession: PRJNA629298, PRJNA629388) harbored 1997, 1162, and 2053 mutations. Some novel mutations have been detected in drugs targets. Similarly, numerous novel variants have also been detected in virulency and evolutionary factors, PE, PPE, and secretory system of MTB isolates. Exploring the genomic variations among the circulating isolates in geographical specific locations might be useful for future drug designing. To the best of our knowledge, this is the first study that provides useful data regarding the insight genomic variations in virulency, evolutionary factors including ESX and PE/PPE as well as drug targets, for better understanding and management of TB in a WHO declared high burden country.
全基因组测序(WGS)是检测耐药性、其他毒力因子遗传多样性以及结核分枝杆菌复合体(MTBC)进化动态的最可靠方法之一。一线抗结核药物是对抗结核分枝杆菌(MTB)的主要武器。然而,耐药性的出现仍然是 2030 年全球结核病(TB)控制计划的主要障碍,特别是在包括巴基斯坦在内的高负担国家。为了克服耐药性并设计有效的药物,药物靶点以及毒力和进化因素的基因组变异可能有助于更好地理解和设计潜在的抑制剂。在这里,我们旨在寻找巴基斯坦开伯尔-普赫图赫瓦省循环分离株中一线药物靶点以及其他毒力和进化因素的基因组变异。采集样本并进行药物敏感性测试(DST),符合世界卫生组织的标准。将耐药样本进行 WGS 检测。在五个全基因组序列中,三个样本(NCBI 生物项目访问号:PRJNA629298、PRJNA629388)携带 1997、1162 和 2053 个突变。在药物靶点中也检测到一些新的突变。同样,在 MTB 分离株的毒力和进化因子、PE、PPE 和分泌系统中也检测到了大量新的变体。探索特定地理位置的循环分离株中的基因组变异可能有助于未来的药物设计。据我们所知,这是第一项提供有关毒力、进化因子(包括 ESX 和 PE/PPE)以及药物靶点的基因组变异的深入了解的有用数据的研究,有助于在世界卫生组织宣布的高负担国家更好地理解和管理结核病。